Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Recruiting · NCT05986240 · Registry updated 2025-11-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-11-10 | NCT05986240 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Flamingo Therapeutics NV | 1 |
| M.D. Anderson Cancer Center | 1145 |
| Montefiore Medical Center | 93 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| M.D. Anderson Cancer Center, Department of Leukemia | Houston | United States | 1 |
| Montefiore Medical Center | The Bronx | United States | 198 |